Navigation Links
Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer

Roche has made a formal application to the European Medicines Agency (EMEA) to enable the use of Herceptin (trastuzumab) as a viable treatment// for advanced HER2-positive and hormone receptor-positive breast cancer.

The application follows the encouragement received from the international TAnDEM study which showed that the use of Herceptin enhances the median progression-free survival from 2.4 months to 4.8 months.

HER2-positive breast cancer affects almost 20 to 30 percent of women with breast cancer, and is a galloping form of the disease that demands immediate attention due to the tumors growing at a rapid rate with a greater chance of relapse.

Eduard Holdener, Global Head of Roche Pharma Development said, "The results from the TAnDEM study show once again that Herceptin should be the backbone for all HER2-positive breast cancer patients -- it consistently benefits patients regardless of whether it is given in the early- or advanced-stage settings, or whether it is in combination with chemotherapy, hormonal therapy, or as a single agent. This combination offers a new treatment regimen for patients who suffer from a particularly aggressive form of breast cancer, and we are pleased to have been able to progress this application so quickly."
'"/>




Page: 1

Related medicine news :

1. FDA Imposes New Restrictions On Roches Accutane
2. Roche confirms Tamiflu production talks in US
3. Roche offers HIV drug expertise to poor nations
4. Roche Commits More Antiviral Pills To Asia For Bird Flu
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Roche Rolls Out Lung Cancer Drug In India
7. New Lung Cancer Drug Launched By Roche Pharmaceutical
8. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
9. NICE Gives the Final ‘NO’ to Roche’s Tarcva
10. Prostate Cancer Can Be Treated By Application Of LASER Technology
11. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... luxurious collection of unique masks and serums that perfectly fuse the beauty of ... advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th in ...
(Date:8/22/2017)... ... 2017 , ... The old adage “you are what you ... healthy foods. But this well-known piece of nutrition advice ignores that an individual’s ... not only on properties of the food but also on properties of the ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... cycle management (RCM) solutions, announced recently the availability of a new professional fee ... in appreciation for their service to the healthcare industry. E/M coding is complex ...
(Date:8/22/2017)... DFW Metroplex, TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is ... They provide repair and replacement of auto glass for most makes and models, in ... area in the USA. , They have been a family owned business for the ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
Breaking Medicine Technology: